Dose Efficacy in Adhesive Capsulitis
Recruiting
Phase 3
Interventional Study
Adhesive Capsulitis of the Shoulder
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 40 (estimated)
- Sponsor
- University Health Network, Toronto · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this study is to find out if the treatment of adhesive capsulitis with 40 mg of methylprednisolone in combination with a hydrodilatation is comparable to 80 mg of methylprednisolone for pain reduction, improving shoulder mobility, and reducing side effects.
Researchers will enroll 40 people in this study which is taking place solely at the Toronto Rehabilitation Institute, Universi…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* \>18 years of age
* Diagnostic of adhesive capsulitis of the shoulder
Exclusion Criteria:
* Injection received in the affected shoulder \< 3 months ago (any kind)
* History of previous surgery in the affected shoulder
* Glenohumeral osteoarthritis more than mild on the xray
…
Contacts